Literature DB >> 29212947

Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.

Christophe Pedros1, Ann J Canonigo-Balancio1, Kok-Fai Kong1,2, Amnon Altman1.   

Abstract

The ability of Tregs to control the development of immune responses is essential for maintaining immune system homeostasis. However, Tregs also inhibit the development of efficient antitumor responses. Here, we explored the characteristics and mechanistic basis of the Treg-intrinsic CTLA4/PKCη signaling pathway that we recently found to be required for contact-dependent Treg-mediated suppression. We show that PKCη is required for the Treg-mediated suppression of tumor immunity in vivo. The presence of PKCη-deficient (Prkch-/-) Tregs in the tumor microenvironment was associated with a significantly increased expression of the costimulatory molecule CD86 on intratumoral CD103+ DCs, enhanced priming of antigen-specific CD8+ T cells, and greater levels of effector cytokines produced by these cells. Similar to mouse Tregs, the GIT/PAK/PIX complex also operated downstream of CTLA4 and PKCη in human Tregs, and GIT2 knockdown in Tregs promoted antitumor immunity. Collectively, our data suggest that targeting the CTLA4/PKCη/GIT/PAK/PIX signaling pathway in Tregs could represent a novel immunotherapeutic strategy to alleviate the negative impact of Tregs on antitumor immune responses.

Entities:  

Keywords:  Cancer immunotherapy; Immunology

Mesh:

Substances:

Year:  2017        PMID: 29212947      PMCID: PMC5752292          DOI: 10.1172/jci.insight.95692

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  62 in total

Review 1.  The emerging understanding of myeloid cells as partners and targets in tumor rejection.

Authors:  Miranda L Broz; Matthew F Krummel
Journal:  Cancer Immunol Res       Date:  2015-04       Impact factor: 11.151

2.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.

Authors:  Chunhong Zheng; Liangtao Zheng; Jae-Kwang Yoo; Huahu Guo; Yuanyuan Zhang; Xinyi Guo; Boxi Kang; Ruozhen Hu; Julie Y Huang; Qiming Zhang; Zhouzerui Liu; Minghui Dong; Xueda Hu; Wenjun Ouyang; Jirun Peng; Zemin Zhang
Journal:  Cell       Date:  2017-06-15       Impact factor: 41.582

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Dynamic recruitment of PAK1 to the immunological synapse is mediated by PIX independently of SLP-76 and Vav1.

Authors:  Hyewon Phee; Robert T Abraham; Arthur Weiss
Journal:  Nat Immunol       Date:  2005-05-01       Impact factor: 25.606

5.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 8.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

Authors:  Thomas F Gajewski; Seng-Ryong Woo; Yuanyuan Zha; Robbert Spaapen; Yan Zheng; Leticia Corrales; Stefani Spranger
Journal:  Curr Opin Immunol       Date:  2013-04-08       Impact factor: 7.486

9.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

Authors:  Nikhil S Joshi; Elliot H Akama-Garren; Yisi Lu; Da-Yae Lee; Gregory P Chang; Amy Li; Michel DuPage; Tuomas Tammela; Natanya R Kerper; Anna F Farago; Rebecca Robbins; Denise M Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Immunity       Date:  2015-09-01       Impact factor: 31.745

10.  Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.

Authors:  Kok-Fai Kong; Guo Fu; Yaoyang Zhang; Tadashi Yokosuka; Javier Casas; Ann J Canonigo-Balancio; Stephane Becart; Gisen Kim; John R Yates; Mitchell Kronenberg; Takashi Saito; Nicholas R J Gascoigne; Amnon Altman
Journal:  Nat Immunol       Date:  2014-04-06       Impact factor: 25.606

View more
  10 in total

1.  Protein Kinase C-η Deficiency Does Not Impair Antiviral Immunity and CD8+ T Cell Activation.

Authors:  Hsin-Yu Liu; Christophe Pedros; Kok-Fai Kong; Ann J Canonigo-Balancio; Amnon Altman
Journal:  J Immunol       Date:  2020-03-20       Impact factor: 5.422

2.  MKL-1 is a coactivator for STAT5b, the regulator of Treg cell development and function.

Authors:  Yuan Xiang; Jun Wang; Jia Peng Li; Wei Guo; Feng Huang; Hui Min Zhang; Han Han Li; Zhou Tong Dai; Zi Jian Zhang; Hui Li; Le Yuan Bao; Chao Jiang Gu; Kun Chen; Tong Cun Zhang; Xing Hua Liao
Journal:  Cell Commun Signal       Date:  2020-07-09       Impact factor: 5.712

Review 3.  Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.

Authors:  Christophe Pedros; Amnon Altman; Kok-Fai Kong
Journal:  Front Immunol       Date:  2018-10-22       Impact factor: 7.561

Review 4.  Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.

Authors:  Duaa O Khair; Heather J Bax; Silvia Mele; Silvia Crescioli; Giulia Pellizzari; Atousa Khiabany; Mano Nakamura; Robert J Harris; Elise French; Ricarda M Hoffmann; Iwan P Williams; Anthony Cheung; Benjamin Thair; Charlie T Beales; Emma Touizer; Adrian W Signell; Nahrin L Tasnova; James F Spicer; Debra H Josephs; Jenny L Geh; Alastair MacKenzie Ross; Ciaran Healy; Sophie Papa; Katie E Lacy; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

5.  Requirement of Mitochondrial Transcription Factor A in Tissue-Resident Regulatory T Cell Maintenance and Function.

Authors:  Zheng Fu; Jian Ye; Joseph W Dean; John W Bostick; Samuel E Weinberg; Lifeng Xiong; Kristen N Oliff; Zongming E Chen; Dorina Avram; Navdeep S Chandel; Liang Zhou
Journal:  Cell Rep       Date:  2019-07-02       Impact factor: 9.423

6.  Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling.

Authors:  Lucas A Salas; Ze Zhang; Devin C Koestler; Rondi A Butler; Helen M Hansen; Annette M Molinaro; John K Wiencke; Karl T Kelsey; Brock C Christensen
Journal:  Nat Commun       Date:  2022-02-09       Impact factor: 14.919

7.  Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.

Authors:  Nasser K Altorki; Alain C Borczuk; Sebron Harrison; Lauren K Groner; Bhavneet Bhinder; Vivek Mittal; Olivier Elemento; Timothy E McGraw
Journal:  Cell Rep       Date:  2022-04-05       Impact factor: 9.995

Review 8.  Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy.

Authors:  Gil-Ran Kim; Je-Min Choi
Journal:  Mol Cells       Date:  2022-07-27       Impact factor: 4.250

9.  Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy.

Authors:  Huayao Li; Lijuan Liu; Cun Liu; Jing Zhuang; Chao Zhou; Jing Yang; Chundi Gao; Gongxi Liu; Qingliang Lv; Changgang Sun
Journal:  Med Sci Monit       Date:  2018-08-15

10.  Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.

Authors:  Hsin-Yu Liu; Christophe Pedros; Kok-Fai Kong; Ann J Canonigo-Balancio; Wen Xue; Amnon Altman
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.